University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Beating the asthma mythson May 17, 2021 at 6:18 pm
This is a challenging time for your lung health, especially if you suffer from chronic respiratory illnesses like asthma ...
- Pivotal data at ATS 2021 show Dupixent(R) (dupilumab) significantly reduced asthma attacks and improved lung function in childrenon May 17, 2021 at 2:30 pm
PARIS and TARRYTOWN, N.Y. - May 17, 2021 - Detailed results from a Phase 3 trial showed Dupixent (R) (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung ...
- Why Asthma Isn't 'Just Asthma'on May 17, 2021 at 2:24 pm
In the past year and a half, almost two years, now my goal has been to educate and bring to light that asthma isn’t “just asthma,” as you hear people so often say when talking about the condition or ...
- Dr Joe Zein Discusses How Sex, Age Differences Affect Asthmaon May 17, 2021 at 7:46 am
Joe Zein, MD, PhD, outlines how sex and age differences can impact asthma disease course. Asthma diagnosis is more common and more severe in younger boys before puberty, said Joe Zein, MD, PhD, a ...
- Sanofi, touting new data, sees 'best-in-class' case for Dupixent in pediatric asthmaon May 17, 2021 at 7:00 am
Now, with a potential approval in childhood asthma forthcoming, Sanofi is touting new data that could make the medicine a "best-in-class" treatment, the company says.
- Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Childrenon May 17, 2021 at 7:00 am
FDA decision for children with moderate-to-severe asthma expected by October 21, 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that detailed results from a Phase 3 ...
- Family history, race and sex linked to higher rates of asthma in childrenon May 16, 2021 at 9:00 pm
A national study on childhood asthma led by Henry Ford Health System has found that family history, race and sex are associated in different ways with higher rates of asthma in children.
- Living in redlined areas associated with lower lung function in those with asthmaon May 14, 2021 at 7:35 am
Individuals with asthma who live in redlined neighborhoods have worse lung function than those in locales that excluded Black people and benefited from decades of inequitable wealth accumulation at ...
- New drug shows promise against tough-to-manage asthmaon May 13, 2021 at 8:30 am
An experimental injectable drug appears more versatile than existing medications in treating people with different forms of severe, hard-to-control asthma, clinical trial results show.
- Tezepelumab Cuts Severe Asthma Exacerbations by More Than Half, Study Sayson May 12, 2021 at 2:06 pm
A novel biologic for severe asthma reduced exacerbations by 56%, according to a study published Wednesday in The New England Journal of Medicine.
via Bing News